查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1768464

全球栓塞治療市場

Embolotherapy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 282 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球栓塞治療市場規模將達 85 億美元

全球栓塞治療市場規模預計在2024年為54億美元，預計到2030年將達到85億美元，在2024-2030年的分析期間內，複合年成長率為7.7%。栓塞劑是本報告分析的細分市場之一，預計其複合年成長率為8.2%，到分析期結束時將達到67億美元。支援設備細分市場在分析期間內的複合年成長率預計為5.8%。

美國市場預計將達到 14 億美元，中國市場複合年成長率將達到 11.3%

美國栓塞市場規模預計2024年達到14億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到21億美元，在2024-2030年的分析期間內，複合年成長率為11.3%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為4.0%和7.1%。在歐洲，預計德國市場的複合年成長率為4.8%。

全球栓塞治療市場—主要趨勢與促進因素摘要

栓塞治療如何徹底改變微創治療？

栓塞術是一種尖端的微創治療方法，它透過有效阻斷流向目標部位的血流，幫助治療各種複雜疾病，包括癌症、血管異常和創傷性出血，從而重新定義醫學領域。栓塞術最初用於治療消化道出血和創傷，現已顯著發展，應用範圍擴展到腫瘤學和婦女健康等領域。在腫瘤學領域，經動脈化療栓塞術 (TACE) 和放射栓塞術被廣泛用於治療肝癌，在切斷腫瘤血液供應的同時，進行局部化療，最大限度地減少對周圍組織的損傷。同樣，對於尋求非手術解決方案的女性來說，子宮肌瘤栓塞術已成為一種比子宮切除術更受歡迎、侵入性更小、恢復更快的替代方案。除了這些領域之外，栓塞術在靜脈曲張治療、動脈畸形治療以及緊急創傷病例的出血控制中也變得很常見，為醫療保健提供者在複雜情況下提供了一種有效的、通常可以挽救生命的選擇。

除了其主要應用之外，栓塞療法還因其能夠治療不適合傳統外科手術的高風險患者而受到認可。它的微創特性可以降低併發症的風險、縮短住院時間並加快復原時間。這種治療方法由於其多功能性而越來越受到醫療保健提供者的青睞，無論是在門診還是加護病房中，它都可以根據個別患者的需求進行客製化。此外，在創傷病例中，栓塞療法的快速部署和內出血的精確控制可以穩定患者，以便進行進一步的干涉。由於這些優勢，栓塞療法仍然是介入放射學中的關鍵技術，預計將在複雜醫療狀況的管理中發揮越來越重要的作用，重點是以患者為中心的護理。

哪些技術進步推動了栓塞治療的發展？

影像處理和導管系統的最新創新將栓塞治療推向了新的高度，使其在各種臨床環境中更加安全、精準且療效顯著。包括高清螢光透視、MRI引導介入和3D影像在內的影像學進步，使醫護人員能夠清楚地觀察目標部位，從而精準注射栓塞劑，並最大限度地減少對周圍健康組織的影響。隨著影像技術的進步，栓塞材料本身也在不斷發展，藥物釋放型微球和生物分解性微球等創新材料可提供雙重益處。這些先進材料可以同時阻斷血流，並持續提供局部藥物治療，從而能夠更全面地治療腫瘤和其他複雜病變。成像技術與先進材料的結合顯著改善了患者的預後，並擴大了栓塞治療的適用範圍。

導管技術的另一項重大進展是其發展，新型微導管和可操控導管的設計使其能夠在複雜的血管網路中更好地導航。這種控制水平對於需要精準定位的手術至關重要，例如針對腦部等敏感區域的腫瘤或異常血管。此外，機器人輔助栓塞術正成為一種新興趨勢，它使臨床醫生能夠以更高的精度執行複雜的手術，並減少輻射暴露。人工智慧 (AI) 和機器學習與栓塞術的融合也即將出現，這為治療結果提供了預測性見解，並指導個人化治療方案。總而言之，這些技術進步正在將栓塞術轉變為一種高度精準有效的治療方案，滿足現代醫療保健不斷變化的需求，並拓展微創治療的可能性。

為什麼栓塞治療的新用途不斷出現？

栓塞術的應用範圍正在各個治療領域迅速擴展，這主要是因為它具有微創性，並且能夠有效治療難以觸及的病變。例如，在腫瘤學領域，栓塞術不僅對肝癌有效，而且對腎癌、前列腺癌和其他類型的腫瘤也有效，為患者提供了一種創傷更小、副作用更少的傳統手術替代方案。栓塞術在創傷護理中也越來越常見，其控制內出血的能力使其成為在其他外科手術干預前穩定患者病情的重要工具。在女性健康領域，栓塞術在子宮肌瘤栓塞等手術中越來越受歡迎，吸引了那些尋求非手術治療方案（而非子宮切除術）、恢復更快、風險更低的患者。這些應用凸顯了栓塞術成為多個醫學領域基礎治療的潛力。

栓塞治療的多功能性也延伸到心血管應用，例如治療動靜脈畸形 (AVM) 和透過調節異常血流來預防動脈瘤。隨著個人化醫療的不斷發展，這種治療方法的適應性使其能夠根據患者的具體需求進行客製化，從而提供了將栓塞劑與標靶治療相結合的可能性。這種個人化方法有望支持治療領域的進一步擴展，因為臨床醫生可以根據個別患者情況量身定做治療方案。此外，栓塞治療也適用於治療消化器官系統和泌尿器官系統，因為它的精確性和微創性使其適用於精細結構。這項技術的廣泛應用不僅會改善患者的治療效果，而且還使醫療保健提供者能夠為日益多樣化的醫療狀況提供先進的治療選擇，從而使栓塞成為現代介入醫學的關鍵組成部分。

推動全球栓塞治療市場成長的因素是什麼？

栓塞市場的成長受多種因素驅動，主要源自於技術進步、終端應用的不斷拓展以及醫療保健偏好的演變。高清影像和精密導管設計等技術創新提高了栓塞手術的精準度，使栓塞手術成為許多治療領域的可靠選擇。這在腫瘤學領域尤其重要，該手術的微創性和腫瘤標靶有效性使其在腫瘤治療中的應用日益廣泛，尤其是在肝癌和腎癌病例中。此外，藥物釋放型和生物分解性栓塞劑的研發擴大了治療範圍，使切斷血液供應和局部藥物治療的雙重作用成為可能。

擴大終端用途也在市場成長中發揮關鍵作用，栓塞治療擴大應用於創傷護理、婦女健康、心血管應用，甚至泌尿系統和胃腸病學等新興領域。此外，以患者為中心的醫療保健趨勢和對微創手術不斷成長的需求進一步推動了其應用，因為患者尋求恢復時間更快、併發症風險更低的替代療法。人口老化和包括癌症和血管疾病在內的慢性病盛行率上升，鞏固了對栓塞治療作為有效且有針對性的干涉措施的需求。醫療保健提供者和製造商之間的策略合作也透過促進創新和提高全球（尤其是在新興市場）先進解決方案的可近性來支持市場成長。綜合起來，這些因素有望在技術創新、應用擴展以及現代醫療保健向精準和微創治療轉變的推動下，實現栓塞治療的持續成長。

部分

產品類別（栓塞劑、支持裝置）；適應症（癌症、周邊血管疾病、神經系統疾病、泌尿系統及腎臟疾病、胃腸道疾病）

受訪公司範例

  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP21718

Global Embolotherapy Market to Reach US$8.5 Billion by 2030

The global market for Embolotherapy estimated at US$5.4 Billion in the year 2024, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Embolic Agents, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the Support Devices segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.3% CAGR

The Embolotherapy market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Embolotherapy Market - Key Trends & Drivers Summarized

How Is Embolotherapy Revolutionizing Minimally Invasive Treatments?

Embolotherapy, a cutting-edge minimally invasive procedure, is redefining the landscape of medical treatments by effectively blocking blood flow to targeted areas, facilitating treatment for a variety of complex conditions such as cancer, vascular anomalies, and trauma-related bleeding. Initially employed to manage gastrointestinal bleeding and traumatic injuries, embolotherapy has evolved significantly, with applications expanding to fields like oncology and women’s health. In oncology, transarterial chemoembolization (TACE) and radioembolization are widely used for liver cancer treatment, depriving tumors of blood supply while delivering localized chemotherapy, minimizing damage to surrounding tissues. Similarly, uterine fibroid embolization has emerged as a preferred alternative to hysterectomy for women seeking non-surgical solutions, offering a less invasive, quicker recovery pathway. Beyond these areas, embolotherapy has become a popular choice in treating varicose veins, managing arterial malformations, and controlling bleeding in emergency trauma cases, providing healthcare providers with an efficient and often life-saving option in complex scenarios.

Beyond its primary applications, embolotherapy is recognized for its ability to manage high-risk patients who may not be ideal candidates for traditional surgical procedures. With its minimally invasive nature, the procedure reduces the overall risk of complications, shortens hospital stays, and decreases recovery time, factors that resonate with patient preferences for treatment. The procedure’s versatility allows it to be tailored to individual patients’ needs, whether in outpatient settings or within intensive care environments, which has broadened its appeal among healthcare providers. Additionally, in trauma cases, embolotherapy’s rapid deployment and precision in controlling internal bleeding can stabilize patients for further interventions. Given these benefits, embolotherapy continues to be a pivotal technique within interventional radiology and is projected to play an increasingly prominent role in managing complex medical conditions with a focus on patient-centered care.

What Technological Advancements Are Propelling Embolotherapy Forward?

Recent technological breakthroughs in imaging and catheter systems are propelling embolotherapy to new heights, making procedures safer, more precise, and increasingly effective across various clinical settings. Imaging advancements, such as high-definition fluoroscopy, MRI-guided intervention, and 3D imaging, allow healthcare providers to visualize target areas with remarkable detail, ensuring embolic agents are precisely deployed and minimizing impact on surrounding healthy tissue. Alongside these imaging enhancements, embolic materials themselves have evolved, with innovative options like drug-eluting beads and biodegradable microspheres offering dual benefits. These advanced materials block blood flow while simultaneously delivering localized drug therapy over time, enabling a more comprehensive approach to treating tumors and other complex conditions. The combination of imaging technology and advanced materials significantly enhances patient outcomes and broadens the potential applications of embolotherapy.

Another key development is the evolution of catheter technology, with new designs in micro and steerable catheters improving navigation within intricate vascular networks. This level of control is essential in procedures requiring pinpoint accuracy, such as those targeting tumors or abnormal blood vessels in sensitive areas like the brain. Additionally, robotic-assisted embolotherapy is an emerging trend, allowing clinicians to perform complex procedures with increased precision and reduced radiation exposure. The integration of artificial intelligence (AI) and machine learning in embolotherapy is also on the horizon, offering predictive insights into procedure outcomes, which can guide customized treatment plans. Collectively, these technological advancements are transforming embolotherapy into a highly precise, effective treatment option, meeting the evolving demands of modern healthcare and expanding the possibilities for minimally invasive interventions.

Why Are New End-Use Applications for Embolotherapy Emerging?

The scope of embolotherapy is rapidly expanding across a variety of therapeutic areas, largely due to its minimally invasive nature and effectiveness in treating hard-to-reach conditions. In oncology, for example, the procedure has proven effective not only for liver cancer but also for renal, prostate, and other types of tumors, offering patients less invasive alternatives to traditional surgery with fewer side effects. This technique is also becoming more common in trauma care, where its capacity to control internal bleeding makes it a critical tool in stabilizing patients before other surgical interventions. In women’s health, embolotherapy is gaining traction with procedures like uterine fibroid embolization, providing a non-surgical solution that appeals to patients seeking alternatives to hysterectomy, with quicker recovery times and less risk involved. These applications highlight embolotherapy’s potential to become a cornerstone treatment in multiple medical fields.

The versatility of embolotherapy extends to cardiovascular applications, where it is used to treat arteriovenous malformations (AVMs) and prevent aneurysms by regulating abnormal blood flow. As personalized medicine continues to grow, the procedure's adaptability enables it to align with patient-specific needs, offering the possibility of combining embolic agents with targeted therapies. This personalized approach is expected to support further expansion in treatment areas, as clinicians can tailor procedures to individual patient profiles. Additionally, embolotherapy is seeing applications in gastrointestinal and urological treatments, as its precision and minimal invasiveness make it suitable for delicate structures. The broader adoption of this technique is not only improving patient outcomes but also enabling healthcare providers to offer advanced treatment options across an increasing array of medical conditions, reinforcing embolotherapy’s role as a critical tool in modern interventional medicine.

What’s Driving the Growth of the Global Embolotherapy Market?

The growth in the embolotherapy market is driven by several factors, primarily rooted in technological advancements, expanding end-use applications, and evolving healthcare preferences. Technological innovations such as high-definition imaging and sophisticated catheter designs have enhanced procedural precision, making embolotherapy a reliable choice across various therapeutic fields. This is particularly relevant in oncology, where the procedure’s minimally invasive nature and effectiveness in tumor targeting have led to increased adoption, especially in cases of liver and renal cancers. Furthermore, the development of drug-eluting and biodegradable embolic agents has broadened the scope of treatments, allowing for dual-action approaches that block blood supply and deliver localized drug therapy, a feature gaining traction in the oncology sector.

End-use expansion also plays a significant role in market growth, with embolotherapy being increasingly used in trauma care, women's health, cardiovascular applications, and even emerging fields like urology and gastroenterology. Additionally, the trend towards patient-centered healthcare and the growing demand for minimally invasive procedures are further fueling adoption, as patients increasingly seek alternatives with shorter recovery times and lower complication risks. An aging population and rising incidence of chronic diseases, including cancer and vascular disorders, underpin the demand for embolotherapy as an effective, targeted intervention. Strategic collaborations between healthcare providers and manufacturers also support market growth by fostering innovation and making advanced solutions more accessible globally, especially in emerging markets. Together, these factors are positioning embolotherapy for sustained growth, driven by innovation, expanding applications, and a shift towards precision and minimally invasive treatments in modern healthcare.

SCOPE OF STUDY:

The report analyzes the Embolotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Segment (Embolic Agents, Support Devices); Disease Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders, Gastrointestinal Disorders)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Embolotherapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Cancer and Vascular Disorders Expands the Addressable Market for Minimally Invasive Embolotherapy Solutions
    • Increasing Adoption of Minimally Invasive Medical Interventions Spurs Growth in Embolotherapy Techniques Across Key Healthcare Markets
    • Technological Advancements in Embolic Agents Improve Precision and Effectiveness, Driving Broader Adoption of Embolotherapy Solutions
    • Expanding Geriatric Population with Increased Risk of Vascular and Cancer-Related Conditions Propels Market Demand for Embolotherapy Procedures
    • Growing Awareness of Uterine Fibroid Embolization as a Non-Surgical Alternative to Hysterectomy Strengthens the Market for Womens Health Applications
    • Rising Prevalence of Arteriovenous Malformations (AVMs) Drives the Need for Specialized Embolotherapy Solutions to Treat Complex Vascular Malformations
    • Shift Toward Outpatient and Ambulatory Care Settings for Embolotherapy Procedures Expands Access and Drives Cost-Effective Healthcare Delivery
    • Growing Use of Embolization Techniques as Less Invasive Alternatives to Open Surgery in Trauma Cases Boosts Demand for Specialized Embolotherapy Solutions
    • Improved Biocompatibility of Next-Generation Embolic Materials Expands Usage in Multi-Therapeutic Applications, Including Oncology and Gynecology
    • Innovations in Catheter Technologies and Delivery Systems Improve Precision and Safety of Embolotherapy Procedures, Supporting Market Growth
    • Increased Adoption of Drug-Eluting Beads in Embolotherapy Enhances Efficacy in Cancer Treatment, Creating New Growth Opportunities in Oncology
    • Rising Global Healthcare Expenditures and Improved Access to Quality Care Drive Demand for Embolotherapy Solutions in Developed and Emerging Markets
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Embolic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Support Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Peripheral Vascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Urological & Nephrological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Gastrointestinal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Embolotherapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • JAPAN
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • CHINA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • EUROPE
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • FRANCE
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • GERMANY
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Embolotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • INDIA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Embolotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Embolotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • AFRICA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030

IV. COMPETITION